Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

Radiology Partners shares advocacy lessons after big win, with eye toward next legislative battle

"Be the squeaky wheel. This issue was taken care of because physicians stood up,” Rad Partners' Richard Heller, MD, told RSNA attendees. 

Thumbnail

FDA approves new fluorescent imaging agent capable of identifying ovarian cancer

The contrast material detected additional lesions during surgery in 27% of ovarian cancer patients, West Lafayette, Indiana-based On Target Laboratories reported.

Thumbnail

Hyperfine gains FDA clearance for deep learning-based image reconstruction tool

The algorithm will enhance T1, T2 and FLAIR images performed using the portable MRI specialist's Swoop machine, officials said Monday.

Xavier Becerra

HHS chief defends controversial surprise billing provision, urging docs to ‘tighten their belt’

Radiologists and other physicians have slammed one key piece of the rule, believing it will tip the scales in favor of payers. 

Thumbnail

Siemens wins FDA clearance for ‘smart’ mammography workflow software

The tools can load images up to 75% faster than other methods and with fewer clicks, the company said Monday.

computer virtual interview

80% of program directors support virtual radiology residency interviews, but the future is still up for debate

At the same time, they admit "interview hoarding" is a problematic consequence that must be addressed.

American Heart Association responds to nomination of cardiologist Robert Califf for FDA commissioner

The AHA believes the next FDA commissioner should play a key role in influencing public health post-COVID-19.

Thumbnail

CMS officially repeals Trump-era rule granting faster Medicare coverage for breakthrough devices

MCIT would have eliminated lag time between the FDA approving new technologies and the federal payment program covering them.